对先前接受 X 连锁视网膜色素变性 (XLRP) 基因治疗的参与者进行第二只眼治疗的后续研究
一项开放标签、多中心、2 期后续研究,对先前接受过重组腺相关病毒载体 (AAV5 hRKp.RPGR) 治疗的患者进行第二眼治疗,用于因 X 连锁色素性视网膜炎进行基因治疗的成人和儿童色素性视网膜炎 GTP 酶调节因子 (RPGR) 缺陷
The purpose of this study is to assess the safety and tolerability of subretinal delivery of Adeno-associated Virus Vector (AAV5 hRKp.RPGR) gene therapy in adults and children with X-linked retinitis pigmentosa.
研究概览
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Have been treated with AAV5-hRKp.RPGR in study MGT009 and have completed or is currently enrolled in Study MGT010
- Must sign an informed consent form indicating that they understand the purpose and procedures of the study and is willing to participate in the study
- Willing to adhere to the protocol and long-term follow-up
Exclusion Criteria:
- There are no specific exclusion criteria to enroll in this study
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Cohort 1
Participants will receive a dose of AAV5 hRKp.RPGR under the retina (low-dose or intermediate-dose) on Day 1 depending on the dosage administered in study MGT009 (NCT03252847) in the past. After receiving the treatment, participants will be assessed for safety. |
AAV5-hRKp.RPGR will be administered sub-retinally.
其他名称:
|
|
实验性的:Cohort 2
Participants will receive the treatment dose of AAV5 hRKp.RPGR under the retina (low-dose or intermediate-dose) on Day 1 in the second eye once the safety will be determined in Cohort 1. |
AAV5-hRKp.RPGR will be administered sub-retinally.
其他名称:
|
|
其他:Cohort 3
The participants who are not willing to undergo surgery or are not eligible for surgery will be assessed in this cohort. They will be assessed yearly until 5 years after their initial eye surgery in previous study MGT009. |
Participants will not receive any intervention and will undergo follow-up assessment. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Participants With Adverse Events (AE)
大体时间:From baseline up to 5.5 years
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. An AE can be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non investigational) product. |
From baseline up to 5.5 years
|
|
Change from Baseline in Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) Chart Letter Scores
大体时间:Baseline, Months 12, 24, 36, 48 and 60
|
Change from baseline in BCVA by ETDRS chart letter scores in monocular assessment of the second treated eye will be assessed. BCVA was measured using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. An increase in the number of letters read correctly means that vision has improved and vice-versa. |
Baseline, Months 12, 24, 36, 48 and 60
|
|
Change from Baseline in Low Luminance Visual Acuity (LLVA) by ETDRS Chart Letter Score
大体时间:Baseline, Months 12, 24, 36, 48 and 60
|
Change in LLVA by ETDRS chart letter scores from baseline in monocular assessment of second treated eye will be assessed. Visual function assessments included LLVA assessment in each eye by ETDRS letters. The letter score ranges from 0 (worse score) to 100 (best score), and a gain in LLVA from baseline indicates an improvement in visual acuity. |
Baseline, Months 12, 24, 36, 48 and 60
|
合作者和调查者
调查人员
- 研究主任:Study Director、MeiraGTx Ocular UK Ltd
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 74765340RPG2001
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.